{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:13:34Z","timestamp":1790370814186,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research & Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research & Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research & Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.ygyno.2019.12.043","type":"journal-article","created":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T01:10:17Z","timestamp":1578445817000},"page":"535-544","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer"],"prefix":"10.1016","volume":"156","author":[{"given":"Bradley J.","family":"Monk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyros","family":"Triantos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Maul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Knoblauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"McGowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed S.W.","family":"Shalaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ygyno.2019.12.043_bb0005","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ygyno.2016.03.005","article-title":"Moving beyond the platinum sensitive\/resistant paradigm for patients with recurrent ovarian cancer","author":"Alvarez","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.12.043_bb0010","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"5","author":"Colombo","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2019.12.043_bb0015","first-page":"S24","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"6","author":"Ledermann","year":"2016","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2019.12.043_bb0020","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0959-8049(00)00357-9","article-title":"Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action","author":"Erba","year":"2001","journal-title":"Eur. J. Cancer"},{"issue":"8","key":"10.1016\/j.ygyno.2019.12.043_bb0025","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/91008","article-title":"Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair","author":"Takebayashi","year":"2001","journal-title":"Nat. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2019.12.043_bb0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/14737140.2016.1243477","article-title":"Factors to consider and questions to ask in the management of recurrent ovarian cancer: a focus on the role of trabectedin + pegylated liposomal doxorubicin","volume":"16","author":"Gonzalez-Martin","year":"2016","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.ygyno.2019.12.043_bb0035","doi-asserted-by":"crossref","first-page":"496","DOI":"10.18632\/oncotarget.968","article-title":"New activities for the anti-tumor agent trabectedin: taking two birds with one stone","volume":"4","author":"D'Incalci","year":"2013","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.ygyno.2019.12.043_bb0040","doi-asserted-by":"crossref","DOI":"10.4161\/onci.24614","article-title":"Trabectedin: a drug from the sea that strikes tumor-associated macrophages","author":"Allavena","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ygyno.2019.12.043_bb0045","author":"European Medicines Agency"},{"key":"10.1016\/j.ygyno.2019.12.043_bb0050","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1200\/JCO.2009.25.4037","article-title":"Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer","volume":"19","author":"Monk","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.12.043_bb0055","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nature03234","article-title":"The BRCA2 homologue Brh2 nucleates RAD51 filament formation at a dsDNA\u2013ssDNA junction","volume":"433","author":"Yang","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2019.12.043_bb0060","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ejca.2008.01.003","article-title":"Role of homologous recombination in trabectedin-induced DNA damage","volume":"44","author":"Tavecchioa","year":"2008","journal-title":"Eur. J. Canc."},{"issue":"15","key":"10.1016\/j.ygyno.2019.12.043_bb0065","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.ejca.2012.04.001","article-title":"Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis","author":"Monk","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2019.12.043_bb0070","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/annonc\/mdv071","article-title":"Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study","volume":"5","author":"Monk","year":"2015","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2019.12.043_bb0075","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/annonc\/mdv608","article-title":"Prospective phase II trial of trabectedin in BRCA-mutated and\/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial","author":"Lorusso","year":"2016","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2019.12.043_bb0080","first-page":"3251","article-title":"Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells","volume":"7","author":"Takahashi","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2019.12.043_bb0085","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00280-003-0636-6","article-title":"Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies","volume":"52","author":"Meco","year":"2003","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ygyno.2019.12.043_bb0090","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"3","author":"Therasse","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2019.12.043_bb0095","author":"Cancer Therapy Evaluation Program"},{"key":"10.1016\/j.ygyno.2019.12.043_bb0105","first-page":"123","article-title":"L. Phase II trial of weekly trabectedin plus weekly pegylated liposomal doxorubicin for treatment of advanced, persistent or recurrent ovarian carcinoma","author":"Panici","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"Suppl. 5","key":"10.1016\/j.ygyno.2019.12.043_bb0110","article-title":"966POutcomes of the combination trabectedin and pegylated liposomal doxorubicin (T-PLD) in recurrent platinum-sensitive ovarian cancer (OC): a GINECO cohort study","volume":"28","author":"Selle","year":"2017","journal-title":"Ann. Oncol."},{"issue":"Suppl. 5","key":"10.1016\/j.ygyno.2019.12.043_bb0115","article-title":"967PAn observational, multicenter, prospective study of trabectedin plus pegylated liposomal doxorubicin (PLD) in patients with platinum-sensitive recurrent ovarian cancer (PSROC)","volume":"28","author":"Reichert","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2019.12.043_bb0120","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/sj.bjc.6604088","article-title":"A phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens","volume":"12","author":"Krasner","year":"2007","journal-title":"Br. J. Cancer"},{"issue":"11","key":"10.1016\/j.ygyno.2019.12.043_bb0125","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/annonc\/mdp198","article-title":"Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg\/m2 24 h or 1.3 mg\/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer","author":"Del Campo","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2019.12.043_bb0130","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1200\/JCO.2005.09.032","article-title":"Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails","volume":"9","author":"Sessa","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2019.12.043_bb0135","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/annonc\/mdq353","article-title":"Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval","author":"Kaye","year":"2011","journal-title":"Ann. Oncol."},{"issue":"Suppl. 15","key":"10.1016\/j.ygyno.2019.12.043_bb0140","doi-asserted-by":"crossref","first-page":"5551","DOI":"10.1200\/jco.2014.32.15_suppl.5551","article-title":"Trabectedin plus pegylated liposomal doxorubicin (PLD) prior to subsequent platinum chemotherapy in patients with platinum-resistant (PR) recurrent ovarian cancer (ROC): results from OVA-301 follow-up","volume":"32","author":"Colombo","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.12.043_bb0145","first-page":"452","article-title":"Trabectedin plus pegylated liposomal doxorubicin (PLD) prior to subsequent platinum-based chemotherapy in recurrent ovarian cancer (ROC): results from OVA-301 follow-up","volume":"24","author":"Colombo","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2019.12.043_bb0150","author":"U.S. National Library of Medicine"},{"key":"10.1016\/j.ygyno.2019.12.043_bb0155","author":"U.S. National Library of Medicine"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819318736?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819318736?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:48:28Z","timestamp":1758772108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825819318736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0090825819318736"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.12.043","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.12.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}